About the journal
A peer-reviewed, online, open access journal, Antibody Therapeutics provides a forum for the publication of the latest advances and challenges in the discovery, research, development, manufacturing, and methodology of therapeutic antibodies for the global scientific community. Topics include target and antibody discovery, mechanistic research, new technologies and methods, manufacturing, clinical trials, regulation, policies, and more. Antibody Therapeutics article types include original research, reviews, cutting-edge technologies, new methods, news, interviews, and meeting highlights.
Journal metrics
| Clarivate | |
|---|---|
| 2025 Impact Factor | 4.8 |
| Scopus | |
| 2025 CiteScore | 7.8 |
| Immunology And Allergy (Rank by CiteScore) | 57/234 |
| Immunology (Rank by CiteScore) | 62/243 |
| 2025 Source Normalized Impact per Paper (SNIP) | 1.092 |
| 2025 Full Text Usage | 207,842 |
| 2025 Median days from submission to first decision | 30 days |
| 2025 Median days from submission to final decision | 66 days |
Disclaimer
Statements of fact and opinion in the articles in Antibody Therapeutics are those of the respective authors and contributors and not of the Journal, ChAbS, or Oxford University Press, unless otherwise expressly indicated. Neither Oxford University Press, ChAbS, nor the Journal make any representation, express or implied, in respect of the accuracy of the material in the Journal and cannot accept any legal responsibility or liability for any errors or omissions that may be made. Readers should make their own evaluation as to the appropriateness or otherwise of the information included.